Evidence map›Paper›PMID 29181576›Full record

ArticleJournal of cancer research and clinical oncology2018

Expression profile of microRNA-146a along HPV-induced multistep carcinogenesis: a study in HPV16 transgenic mice.

Rita Araújo, Joana M O Santos, Mara Fernandes, Francisca Dias, Hugo Sousa, Joana Ribeiro, Margarida M S M Bastos, Paula A Oliveira, Diogo Carmo, Fátima Casaca and 3 more

Open access · greenAbstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Rita AraújoMolecular Oncology and Viral Pathology Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Rua Dr. António Bernardino de Almeida, 4200-072, Porto, Portugal.
Joana M O SantosMolecular Oncology and Viral Pathology Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Rua Dr. António Bernardino de Almeida, 4200-072, Porto, Portugal.
Mara FernandesMolecular Oncology and Viral Pathology Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Rua Dr. António Bernardino de Almeida, 4200-072, Porto, Portugal.
Francisca DiasMolecular Oncology and Viral Pathology Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Rua Dr. António Bernardino de Almeida, 4200-072, Porto, Portugal.
Hugo SousaMolecular Oncology and Viral Pathology Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Rua Dr. António Bernardino de Almeida, 4200-072, Porto, Portugal.
Joana RibeiroMolecular Oncology and Viral Pathology Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Rua Dr. António Bernardino de Almeida, 4200-072, Porto, Portugal.
Margarida M S M BastosLaboratory for Process Engineering, Environment, Biotechnology and Energy (LEPABE), Faculty of Engineering of the University of Porto (FEUP), Rua Dr. Roberto Frias s/n, 4200-465, Porto, Portugal.
Paula A OliveiraCenter for the Research and Technology of Agro-Environmental and Biological Sciences (CITAB), University of Trás-os-Montes and Alto Douro (UTAD), Quinta de Prados, 5001-911, Vila Real, Portugal.
Diogo CarmoBotelho Moniz Análises Clínicas (BMAC), Rua Sarmento de Beires 153, 4250-449, Porto, Portugal.
Fátima CasacaBotelho Moniz Análises Clínicas (BMAC), Rua Sarmento de Beires 153, 4250-449, Porto, Portugal.
Sandra SilvaBotelho Moniz Análises Clínicas (BMAC), Rua Sarmento de Beires 153, 4250-449, Porto, Portugal.
Rui MedeirosMolecular Oncology and Viral Pathology Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Rua Dr. António Bernardino de Almeida, 4200-072, Porto, Portugal. ruimedei@ipoporto.min-saude.pt.ORCID http://orcid.org/0000-0003-3010-8373
Rui M Gil da CostaMolecular Oncology and Viral Pathology Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Rua Dr. António Bernardino de Almeida, 4200-072, Porto, Portugal.
Universidade do Porto · PTCentro de Genética Clínica · PTUniversity of Trás-os-Montes and Alto Douro · PTFernando Pessoa University · PTInstituto Português de Oncologia Francisco Gentil · PT

Funding

Fundação para a Ciência e a Tecnologia SFRH/BPD/85462/2012Laboratory for Process Engineering, Environment, Biotechnology and Energy - LEPABE POCI-01-0145-FEDER-006939Research Center of the Portuguese Institute of Oncology of Porto CI-IPOP 37-2016
6 · The paper itself

Abstract

purposePersistent human papillomavirus (HPV) infection is associated with the development of certain types of cancer and the dysregulation of microRNAs has been implicated in HPV-associated carcinogenesis. This is the case of microRNA-146a (miR-146a), which is thought to regulate tumor-associated inflammation. We sought to investigate the expression levels of miR-146a during HPV16-mediated carcinogenesis using skin samples from K14-HPV16 transgenic mice which develop the consecutive phases of the carcinogenesis process.

methodsFemale transgenic (HPV

resultsChest skin samples from 24 to 26 weeks-old HPV

conclusionsThese results suggest that HPV16 induces the overexpression of miR-146a in the initial stages of carcinogenesis (hyperplasia and dysplasia), whereas decreases its expression at later stages (CIS). Taken together, these data implicate and suggest different roles of miR-146a in HPV-mediated carcinogenesis.

Indexed as

AnimalsCarcinogenesisFemaleHuman papillomavirus 16HyperplasiaMiceMice, TransgenicMicroRNAsPapillomavirus InfectionsSkinSkin NeoplasmsTranscriptomeMicroRNAsMirn146 microRNA, mouseCarcinoma in situDysplasiaHPV16HyperplasiaK14-HPV16 transgenic miceMiR-146a

Identifiers

PMID29181576
PMCPMC11813442
OpenAlexW2770466820

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.